

Original process
Re-stimulation process
D14
Cryopreservation
D17
SNK DP
D0
D7

FIG. 1



Donor 1_Original method
14
12
10
8
6
4
2
0
PDL
12.15
8.62
IL21+, Type 1, (1)
IL21-, Type 1, (2)
D0
D6
D10
D14
D17
Culture stage

FIG. 2A



Donor 2_Original method
14
12
10
8
6
4
2
0
PDL
11.94
11.48
Type 1 IL21+,
Type 1 IL21-,
D0
D6
D10
D14
D17
Culture stage

FIG. 2B



Donor 1_original method
Expansion fold (x)
5,000
4,500
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
0
4,560
394
※Type 1. (I)
※Type 1. IL21-.
D0
D6
D10
D14
D17
Culture condition
IL21-.

FIG. 3A



Donor 2_Original method
Expansion fold(x)
5,000
4,000
3,000
2,000
1,000
0
3,960
2,860
※Type 1 IL21+.
※Type 1 IL21-.
D0
D6
D10
D14
D17
Culture stage

FIG. 3B



Donor 1
25
20
15
10
5
0
PDL
Re-stimulation
22.62
22.40
18.25
18.12
Type 1.IL21+/+
Type 1.IL21+/-
Type 1.IL21-/+
Type 1.IL21-/-
D0
D6
D10
D14
D20
D24
D28
D31
Culture day

FIG. 4A



Donor 2
25.00
20.00
15.00
10.00
5.00
0.00
PDL
Re-stimulation
23.57
23.33
22.10
21.16
Type 1.IL21+/+
Type 1.IL21+/-
Type 1.IL21-/+
Type 1.IL21-/-
D0
D6
D10
D14
D20
D24
D28
D31
Culture day

FIG. 4B



Donor 1
8,000,000
7,000,000
6,000,000
5,000,000
4,000,000
3,000,000
2,000,000
1,000,000
0
Expansion fold (X)
Type 1.IL21+/+
Type 1.IL21+/-
Type 1.IL21-/+
Type 1.IL21-/-
7,453,846
5,592,105
313,846
287,692
D0
D6
D10
D14
D20
D24
D28
D31
Culture day

FIG. 5A



Donor 2
14,000,000
12,000,000
10,000,000
8,000,000
6,000,000
4,000,000
2,000,000
0
Expansion fold (X)
Type 1.IL21+/+
Type 1.IL21+/-
Type 1.IL21-/+
Type 1.IL21-/-
12,571,429
10,461,538
4,369,231
2,369,231
D0
D6
D10
D14
D20
D24
D28
D31
Culture day

FIG. 5B



Type 1.(1). (+)IL-21
95.8
98.8
74.6
53.3
100
80
60
40
20
0
Lysis (%)
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 6



Type 1.(2). (-) IL-21
94.2
81.4
55.6
37.7
100
80
60
40
20
0
Lysis (%)
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 7



Type 1. (1)-1. (+) IL-21
Lysis (%)
120
100
80
60
40
20
0
98.1
84.9
72.8
42.9
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 8



Type 1. (1)-2. (-) IL-21
Lysis (%)
120
100
80
60
40
20
0
99.6
83.2
62.2
33.6
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 9



Type 1. (2)-1. (+) IL-21
120
100
80
60
40
20
0
Lysis (%)
89.1
81.0
45.3
31.2
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 10



Type 1. (2)-2. (-) IL-21
120
100
80
60
40
20
0
Lysis (%)
91.6
77.3
46.1
30.8
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 11



CD16
CD337 (NKp30)
CD335 (NKp46)
CD336 (NKp44)
CD314 (NKG2D)
CD244 (2B4)
CD159c (NKG2C)
CD319 (CRACC)

FIG. 12A



CD159a (NKG2A)
CD158a (KIR2DL1)
CD158b (KIR2DL2/DL3)
CD158e (KIR3DL1)
CD62L
CD183 (CXCR3)
CD184 (CXCR4)

FIG. 12B




FIG. 13A




FIG. 13B



PDL
0
5
10
15
20
25
30
35
40
0.50
5.90
10.10
11.44
17.44
20.35
22.13
28.83
33.40
35.06
35.21
1st stimulation
Cell culture
Frozen (3M)
2nd stimulation
Cell culture
3rd stimulation
Cell culture
DAY0
DAY6
DAY10
DAY16
Frozen/Thawing
DAY20
DAY24
DAY28
DAY34
DAY38
DAY42
DAY46

FIG. 14A



Expansion fold
Expansion fold(x)
4.5E+10
4E+10
3.5E+10
3E+10
2.5E+10
2E+10
1.5E+10
1E+10
5E+09
50
60
1,160
2,800
179,260
1,344,600
4,839,400
483,840,000
11,491,200,000
36,388,396,800
40,219,200,000
DAY0
DAY6
DAY10
DAY14
DAY20
DAY24
DAY28
DAY34
DAY38
DAY42
DAY46
Culture day

FIG. 14B